Pfizer: Pfizer advances bold vision for future of cancer care at the ASCO 2025 annual meeting

Pfizer Inc. will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 to June 3 in Chicago. Data from more than 60 company-sponsored, investigator-sponsored, and collaborative research abstracts, including 9 oral presentations and 6 rapid oral presentations, will be presented across Pfizer's key tumor areas, including breast, genitourinary, hematologic, and thoracic cancers, as well as colorectal cancer. "This has already been a significant year for Pfizer's Oncology pipeline, with multiple phase 3 data readouts and regulatory approvals, and the initiation of pivotal registrational programs across our major tumour areas of focus," said Chris Boshoff, MD, PhD, chief scientific officer and president, research & development, Pfizer. "The depth and diversity of our data presentations at ASCO are building on that momentum to bring us closer to our goal of delivering eight breakthrough cancer medicines by 2030." Pfizer will have two late-breaking oral presentations featured in ASCO's embargoed pre-meeting press briefing on May 27. These include the primary analysis of the pivotal overall survival (OS) and progression-free survival (PFS) results from the phase 3 BREAKWATER study investigating Braftovi (encorafenib)in combination with cetuximab (marketed as Erbitux) and mFOLFOX6 in patients with BRAF V600E-mutant metastatic colorectal cancer, as well as the first presentation of the PFS results from the phase 3 VERITAC-2 study of vepdegestrant in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer (a/mBC) in partnership with Arvinas. Pfizer will share additional updates from key late-stage programs, including five-year survival data from the phase 3 ARCHES study of Xtandi (enzalutamide) in combination with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer (mHPSC), and the first combination data for Elrexfio (elranatamab) + daratumumab + lenalidomide from the ongoing MagnetisMM-6 study in patients with transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM). Pfizer will also share new findings highlighting the company's strategy to explore novel vedotin antibody-drug conjugates (ADCs) in combination with immune checkpoint inhibitors to potentially enhance anti-tumour activity. For the first time, Pfizer will present encouraging phase 1 data on two novel investigational ADCs in combination with pembrolizumab in thoracic cancers: sigvotatug vedotin (SV), an integrin beta-6 (IB6)-directed ADC, in lung cancer and head and neck cancers, and PDL1V (PF-08046054), a PD-L1 directed ADC, in head and neck cancers. Additionally, new exploratory analyses will be presented from the pivotal EV-302 trial with Padcev (enfortumab vedotin) in combination with Keytruda (pembrolizumab) in patients with previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC). Several presentations will highlight updated results from ongoing phase 1 studies that inform the dosing strategy in registrational programmes for two molecules targeting epigenetic regulators: mevrometostat, an investigational EZH2 inhibitor being evaluated in combination with Xtandi for metastatic castration-resistant prostate cancer (mCRPC); and PF-07248144, a potential first-in-class KAT6 inhibitor for ER+/HER2- metastatic breast cancer (mBC). "Our data at ASCO this year reflect how we are strategically progressing our deep pipeline of next generation cancer medicines while simultaneously extending the impact of our foundational therapies to reach more people living with cancer," said Megan O'Meara, head of early-stage development and interim head of late-stage development, Pfizer Oncology. "Important early-stage updates highlight our extensive pipeline and depth within our core cancer types, as we advance up to nine new pivotal phase 3 trials this year." Key ASCO presentations -- Colorectal cancers: Braftovi: A late-breaking session will detail PFS and OS results from the phase 3 BREAKWATER study of Braftovi in combination with cetuximab and mFOLFOX6 chemotherapy inBRAF V600E-mutant metastatic colorectal cancer, further establishing the benefit of the Braftovi combination regimen following its FDA accelerated approval in late 2024. These pivotal study results follow the topline results announcement for PFS and OS and the objective response rate (ORR) results presented at ASCO GI. These new data will also be featured in the ASCO press program. Breast cancer Vepdegestrant: In a late-breaking session, PFS data will be presented for the first time from the phase 3 VERITAC-2 study of vepdegestrant, a Protac ER degrader, in ER+/HER2- a/mBC. These detailed data follow the topline results from VERITAC-2 announced earlier this year and will also be featured in the ASCO press programme. PF-07248144 (KAT6 inhibitor): A rapid oral presentation will highlight dose optimization data from an ongoing phase 1 study for PF-07248144, a potential first-in-class KAT6 inhibitor, in patients with ER+/HER2- mBC. These results support the recommended dosing for PF-07248144 ahead of the phase 3 trial initiation in second-line mBC planned for 2H 2025. Ibrance (palbociclib): Roche will present detailed results from the OS analysis of the phase 3 INAVO120 study investigating Itovebi (inavolisib) in combination with Ibrance and fulvestrant in patients withPIK3CA-mutated, HR+/HER2-, endocrine-resistant, locally a/mBC. This presentation will be featured in ASCO's embargoed pre-meeting press briefing on May 21. Genitourinary cancers Xtandi: Five-year follow-up overall survival data from the ARCHES study of Xtandi in combination with androgen deprivation therapy in patients with mHSPC will be featured in an oral presentation. In addition, updates from the Astellas-supported, investigator-sponsored ENZAMET phase 3 research study, led by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) and sponsored by the University of Sydney, will also be presented, including 8 year-outcomes in men with mHSPC. These presentations further underscore the value of Xtandi across approved indications. Mevrometostat: A poster presentation will highlight pharmacokinetic and safety data from the ongoing phase 1 study for mevrometostat, an investigational EZH2 inhibitor, in combination with Xtandi. These updated data further inform the dosing strategy for mevrometostat in a robust registrational program that includes two phase 3 trials in mCRPC, and a third trial in metastatic castration-sensitive prostate cancer (mCSPC) that is planned to start in 1H 2025. Padcev: Additional updates from the phase 3 EV-302 study of PADCEV in combination with Keytruda in previously untreated la/mUC will be presented, including an oral presentation with exploratory analysis of responders. Hematologic cancers Elrexfio: Initial safety and efficacy results from Part 1 of the ongoing MagnetisMM-6 study of Elrexfio in combination with daratumumab and lenalidomide in patients with newly diagnosed MM that are not eligible for transplant will be presented as an oral presentation. Part 1 of the ongoing MagnetisMM-6 study evaluates the optimal dose of the Elrexfio combination regimen in patients with RRMM or NDMM to determine the recommended phase 3 dose for part 2. Thoracic cancers Sigvotatug vedotin (SV): Phase 1 results for SV, an IB6-directed vedotin ADC, in combination with pembrolizumab in non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) will be featured in a rapid oral presentation. This initial combination data for SV with pembrolizumab support a phase 3 study in first line PD-L1-High NSCLC, initiated this year. The data also support the overall SV trial program that includes an ongoing phase 3 monotherapy trial in second line+ NSCLC. PDL1V (PF-08046054): Two poster presentations will highlight interim phase 1 results for PDL1V, a PD-L1 directed vedotin ADC, as monotherapy in NSCLC and initial safety and efficacy data in combination with pembrolizumab in patients with first-line recurrent or metastatic (r/m) HNSCC. These data provide additional support for the initiation of the two pivotal phase 3 trials planned for PDL1V in 2025 in second line+ NSCLC and first line r/mHNSCC. Pfizer is continuing its commitment to help non-scientists understand the latest findings with the development of abstract plain language summaries (APLS) for company-sponsored research being presented at ASCO, which are written in non-technical language.